Novo Nordisk A/S - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US6701002056
35,82 € ↓ -1,80 (-4,78%)
2026-06-05
DEL PRIS
SecurityDE:NOVA / Novo Nordisk A/S - Depositary Receipt (Common Stock)
InstitutionWendell David Associates Inc
Latest Disclosed Ownership59,058 shares
Latest Disclosed Value $ 2,170
Wendell David Associates Inc reports 1.23% decrease in ownership of NOVA / Novo Nordisk A/S - Depositary Receipt (Common Stock)

On April 23, 2026 - Wendell David Associates Inc filed a 13F-HR form disclosing ownership of 59,058 shares of Novo Nordisk A/S - Depositary Receipt (Common Stock) (DE:NOVA) valued at $1,863,280 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 59,793 shares of Novo Nordisk A/S - Depositary Receipt (Common Stock). This represents a change in shares of -1.23% during the quarter. The current value of the position is $2,115,458 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-23 2026-03-31 13F Novo Nordisk ADR COMM 670100205 59,058 -735 -1.23 2 -33.33 0.2362
2026-01-30 2025-12-31 13F Novo Nordisk ADR COMM 670100205 59,793 -6,054 -9.19 3 0.00 0.3090
2025-10-30 2025-09-30 13F Novo Nordisk ADR COMM 670100205 65,847 -6,955 -9.55 4 -40.00 0.3607
2025-07-29 2025-06-30 13F Novo Nordisk ADR COMM 670100205 72,802 -3,975 -5.18 5 0.00 0.5054
2025-04-18 2025-03-31 13F Novo Nordisk ADR COMM 670100205 76,777 -70 -0.09 5 -16.67 0.5319
2025-01-17 2024-12-31 13F Novo Nordisk ADR COMM 670100205 76,847 225 0.29 7 -33.33 0.6536
2024-10-21 2024-09-30 13F Novo Nordisk ADR COMM 670100205 76,622 -500 -0.65 9 -18.18 0.8725
2024-07-22 2024-06-30 13F Novo Nordisk ADR COMM 670100205 77,122 -100 -0.13 11 22.22 1.1217
2024-04-22 2024-03-31 13F Novo Nordisk ADR COMM 670100205 77,222 -248 -0.32 10 12.50 1.0019
2024-01-22 2023-12-31 13F Novo Nordisk ADR COMM 670100205 77,470 7,000 9.93 8 33.33 0.8633
2023-10-20 2023-09-30 13F Novo Nordisk ADR COMM 670100205 70,470 35,335 100.57 6 20.00 0.7541
2023-07-20 2023-06-30 13F Novo Nordisk ADR COMM 670100205 35,135 -569 -1.59 6 0.00 0.6423
2023-04-19 2023-03-31 13F Novo Nordisk ADR COMM 670100205 35,704 -2,015 -5.34 6 0.00 0.6737
2023-01-17 2022-12-31 13F Novo Nordisk ADR COMM 670100205 37,719 0 0.00 5 -99.87 0.6274
2022-10-18 2022-09-30 13F Novo Nordisk ADR COMM 670100205 37,719 0 0.00 3,758 -10.59 0.5056
2022-07-14 2022-06-30 13F Novo Nordisk ADR COMM 670100205 37,719 -349 -0.92 4,203 -0.57 0.5344
2022-04-22 2022-03-31 13F Novo Nordisk ADR COMM 670100205 38,068 -3,800 -9.08 4,227 -9.85 0.4706
2022-01-24 2021-12-31 13F Novo Nordisk ADR COMM 670100205 41,868 49 0.12 4,689 16.79 0.4744
2021-10-19 2021-09-30 13F Novo Nordisk ADR COMM 670100205 41,819 469 1.13 4,015 15.91 0.4476
2021-07-19 2021-06-30 13F Novo Nordisk ADR COMM 670100205 41,350 -1,050 -2.48 3,464 21.16 0.3877
2021-04-20 2021-03-31 13F Novo Nordisk ADR COMM 670100205 42,400 0 0.00 2,859 -3.48 0.3441
2021-01-22 2020-12-31 13F Novo Nordisk ADR COMM 670100205 42,400 0 0.00 2,962 0.61 0.3622
2020-10-20 2020-09-30 13F Novo Nordisk ADR COMM 670100205 42,400 -875 -2.02 2,944 3.88 0.3924
2020-07-17 2020-06-30 13F Novo Nordisk ADR COMM 670100205 43,275 -400 -0.92 2,834 7.80 0.4108
2020-04-16 2020-03-31 13F Novo Nordisk ADR COMM 670100205 43,675 0 0.00 2,629 4.00 0.4447
2020-01-17 2019-12-31 13F Novo Nordisk ADR COMM 670100205 43,675 0 0.00 2,528 11.96 0.3482
2019-10-22 2019-09-30 13F Novo Nordisk ADR COMM 670100205 43,675 -3,625 -7.66 2,258 -6.46 0.3307
2019-07-16 2019-06-30 13F Novo Nordisk ADR COMM 670100205 47,300 -225 -0.47 2,414 -2.90 0.3622
2019-04-11 2019-03-31 13F Novo Nordisk ADR COMM 670100205 47,525 0 0.00 2,486 13.57 0.3870
2019-01-17 2018-12-31 13F Novo Nordisk ADR COMM 670100205 47,525 -1,068 -2.20 2,189 -4.45 0.3940
2018-10-12 2018-09-30 13F Novo Nordisk ADR COMM 670100205 48,593 -1,100 -2.21 2,291 -0.04 0.3568
2018-07-16 2018-06-30 13F Novo Nordisk ADR COMM 670100205 49,693 0 0.00 2,292 -6.33 0.3912
2018-04-11 2018-03-31 13F Novo Nordisk ADR COMM 670100205 49,693 -1,400 -2.74 2,447 -10.76 0.4407
2018-01-16 2017-12-31 13F Novo Nordisk ADR COMM 670100205 51,093 -1,368 -2.61 2,742 8.55 0.4698
2017-10-17 2017-09-30 13F Novo Nordisk ADR COMM 670100205 52,461 0 0.00 2,526 12.27 0.4463
2017-07-18 2017-06-30 13F Novo Nordisk ADR COMM 670100205 52,461 -6,450 -10.95 2,250 11.44 0.4239
2017-04-20 2017-03-31 13F Novo Nordisk ADR COMM 670100205 58,911 -6,895 -10.48 2,019 -14.45 0.3860
2017-01-23 2016-12-31 13F Novo Nordisk ADR COMM 670100205 65,806 -5,325 -7.49 2,360 -20.22 0.4659
2016-10-18 2016-09-30 13F/A-1 Novo Nordisk ADR COMM 670100205 71,131 -2,275 -3.10 2,958 -25.38 0.5835
2016-10-18 2016-09-30 13F Novo Nordisk ADR COMM 670100205 73,406 3,964
2016-07-18 2016-06-30 13F Novo Nordisk ADR COMM 670100205 73,406 -6,525 -8.16 3,964 -8.16 0.7781
2016-04-19 2016-03-31 13F Novo Nordisk ADR COMM 670100205 79,931 -489 -0.61 4,316 -7.46 0.8381
2016-01-19 2015-12-31 13F/A-1 Novo Nordisk ADR COMM 670100205 80,420 1,620 2.06 4,664 9.61 0.9201
2016-01-19 2015-12-31 13F Novo Nordisk ADR COMM 670100205 80,420 4,664
2015-10-16 2015-09-30 13F Novo Nordisk ADR COMM 670100205 78,800 -425 -0.54 4,255 -2.34 0.8734
2015-07-20 2015-06-30 13F Novo Nordisk ADR COMM 670100205 79,225 -150 -0.19 4,357 3.57 0.8452
2015-04-20 2015-03-31 13F Novo Nordisk ADR COMM 670100205 79,375 375 0.47 4,207 26.79 0.8089
2015-01-22 2014-12-31 13F Novo Nordisk ADR COMM 670100205 79,000 750 0.96 3,318 -11.66 0.6475
2014-10-21 2014-09-30 13F Novo Nordisk ADR COMM 670100205 78,250 -100 -0.13 3,756 4.22 0.7829
2014-07-30 2014-06-30 13F/A-1 Novo Nordisk ADR COMM 670100205 78,350 -1,325 -1.66 3,604 -1.66 0.7585
2014-07-24 2014-06-30 13F Novo Nordisk ADR COMM 670100205 79,675 3,665
2014-04-17 2014-03-31 13F Novo Nordisk ADR COMM 670100205 79,675 63,675 397.97 3,665 23.82 0.7968
2014-01-21 2013-12-31 13F Novo Nordisk ADR COMM 670100205 16,000 1,795 12.64 2,960 23.28 0.6494
2013-10-22 2013-09-30 13F/A-1 Novo Nordisk ADR COMM 670100205 14,205 1,160 8.89 2,401 18.74 0.5757
2013-10-21 2013-09-30 13F Novo Nordisk ADR COMM 670100205 2,401 2,401
2013-07-19 2013-06-30 13F Novo-Nordisk ADR COMM 670100205 13,045 13,045 2,022 0.5050
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.